MRNS vs. MIST, VTYX, VIRI, IFRX, EPRX, SAVA, BTAI, EDIT, COYA, and VIGL
Should you be buying Marinus Pharmaceuticals stock or one of its competitors? The main competitors of Marinus Pharmaceuticals include Milestone Pharmaceuticals (MIST), Ventyx Biosciences (VTYX), Virios Therapeutics (VIRI), InflaRx (IFRX), Eupraxia Pharmaceuticals (EPRX), Cassava Sciences (SAVA), BioXcel Therapeutics (BTAI), Editas Medicine (EDIT), Coya Therapeutics (COYA), and Vigil Neuroscience (VIGL). These companies are all part of the "pharmaceutical products" industry.
Marinus Pharmaceuticals vs.
Milestone Pharmaceuticals (NASDAQ:MIST) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking.
Milestone Pharmaceuticals presently has a consensus target price of $13.00, indicating a potential upside of 537.25%. Marinus Pharmaceuticals has a consensus target price of $4.79, indicating a potential upside of 771.56%. Given Marinus Pharmaceuticals' higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Milestone Pharmaceuticals.
86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are held by institutional investors. 9.9% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Marinus Pharmaceuticals received 355 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. However, 69.49% of users gave Milestone Pharmaceuticals an outperform vote while only 66.72% of users gave Marinus Pharmaceuticals an outperform vote.
In the previous week, Milestone Pharmaceuticals had 2 more articles in the media than Marinus Pharmaceuticals. MarketBeat recorded 3 mentions for Milestone Pharmaceuticals and 1 mentions for Marinus Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.63 beat Marinus Pharmaceuticals' score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.
Milestone Pharmaceuticals has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. Milestone Pharmaceuticals' return on equity of -151.82% beat Marinus Pharmaceuticals' return on equity.
Milestone Pharmaceuticals has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
Milestone Pharmaceuticals has higher earnings, but lower revenue than Marinus Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Milestone Pharmaceuticals beats Marinus Pharmaceuticals on 13 of the 19 factors compared between the two stocks.
Get Marinus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Marinus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MRNS) was last updated on 2/22/2025 by MarketBeat.com Staff
Free MRNS Stock Alerts